Santen Pharmaceutical Co., Ltd.

Hitoshi Nakazawa

Yoshihiro Oshita

Isao Matsuoka

Asuka Kamimura

Koji Inagaki

Naoki Matsumoto

Yukihisa Wakabayashi

Toshihiro Ogawa

Takazumi Taniguchi

Takahiro Akaishi

The present invention aims to find a novel pharmaceutical use of omidenepag, esters thereof, or salts thereof. The present inventors have made intensive studies to find a novel pharmaceutical use of omidenepag, an ester thereof, or a salt thereof, and have found as a result that omidenepag, an ester thereof, or a salt thereof significantly dilates retinal blood vessels, and significantly increases blood flow. Therefore, omidenepag, an ester thereof, or a salt thereof is expected to protect retinal nerve cells and be useful for prevention and/or treatment of ophthalmic diseases involving retinal nerve cell disorder.

Drug containing pyridylaminoacetic acid compound

An ophthalmic solution, which comprises diquafosol tetrasodium salt and is free from benzalkonium chloride, treats onset and/or exacerbation of dry eye symptom caused by wearing soft contact lenses.

Therapeutic agent for dry eye characterized by being applied to eye of dry eye patient wearing soft contact lens

Provided is an aqueous ophthalmic solution comprising diquafosol or a salt thereof at a concentration of 0.1% to 10% (w/v) and a chlorhexidine at a concentration of 0.0001% to 0.1% (w/v).

Aqueous ophthalmic solution

Growing community of inventors

Ikoma, Japan

Hitoshi Nakazawa